Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.
The prognosis of uncorrected severe mitral regurgitation (MR) is poor, however there is limited data on the prognosis of MR across the spectrum of severity. In addition, there is limited data on the prognosis of different causes of MR. We examined the National Echo Database of Australia and linkage with mortality, and text extraction using Natural Language Processing provided by Echo IQ, to address these important issues.
MR-NEDA – Prognosis of mild to severe MR
Topic: Clinical
Date: 25 August
Time: 14:00 – 15:15
Location: Vilnius
Type: Late-Breaking Science
Speaker: David Playford
DASE-AI: Detect Aortic Stenosis by Echo with Artificial Intelligence
Topic: Echocardiography
Date: 27 August
Time: 14:00 – 15:20
Location: Bratislava
Type: Late-Breaking Science
Speaker: Geoff Strange
A clinical trial of an artificial intelligence automated alert system (AI-AAS) to correctly identify all cases of severe aortic stenosis by scrutinizing routine echocardiographic reports has yielded groundbreaking results.
Join in the ESC conversation as we discuss the intersection of artificial intelligence, structural heart disease, and the future of cardiac care.
Book a time with us:
Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.
#aiwithheart
EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full
phenotyping capabilities will be available pending FDA approval.
All rights reserved. Copyright © 2023 Echo IQ.
Designed and Developed by Brand for Brands.